32. Consolidated companies as of 31 December 2021
Name of the subsidiary |
Country |
% voting right Galapagos NV |
Change in % voting right previous period |
|---|---|---|---|
Galapagos Biopharma Belgium BV |
Belgium |
100% |
|
Galapagos Biopharma Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos Biopharma Spain S.L.U. |
Spain |
100% |
|
Galapagos Biopharma Italy S.r.l. |
Italy |
100% |
|
Galapagos Biopharma Germany GmbH |
Germany |
100% |
|
Galapagos Biopharma Sweden AB |
Sweden |
100% |
100% |
Galapagos Biopharma Norway AS |
Norway |
100% |
100% |
Galapagos Biopharma Finland Oy |
Finland |
100% |
100% |
Galapagos Biopharma Denmark ApS |
Denmark |
100% |
100% |
Galapagos Biopharma Austria GmbH |
Austria |
100% |
100% |
Galapagos Biopharma Ireland Ltd |
Ireland |
100% |
100% |
Galapagos Biotech Ltd |
United Kingdom |
100% |
|
Galapagos B.V. |
The Netherlands |
100% |
|
Galapagos GmbH |
Switzerland |
100% |
|
Galapagos, Inc. |
United States |
100% |
|
Galapagos NV |
Belgium |
Parent company |
|
Galapagos Real Estate Belgium BV |
Belgium |
100% |
|
Galapagos Real Estate Netherlands B.V. |
The Netherlands |
100% |
|
Galapagos SASU |
France |
100% |
|
Fidelta d.o.o. |
Croatia |
0% |
(100%) |
Xenometrix, Inc. in liquidation |
United States |
100% |
|
On 4 January 2021 we closed the sale of our fee-for-service business Fidelta. Selvita S.A. acquired 100% of the outstanding shares in Fidelta.
In 2021, the following new entities were incorporated: Galapagos Biopharma Sweden AB (Stockholm, Sweden), Galapagos Biopharma Norway AS (Oslo, Norway), Galapagos Biopharma Finland Oy (Helsinki, Finland), Galapagos Biopharma Denmark ApS (Copenhagen, Denmark), Galapagos Biopharma Austria GmbH (Vienna, Austria) and Galapagos Biopharma Ireland Ltd (Dublin, Ireland).
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries.